A comparison of reactive oxygen species metabolism in the rat aorta and vena cava: Focus on xanthine oxidase

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 295, Issue 3, 2008, Pages

  Szasz, Theodora ^a,b   Thompson, Janice M ^a   Watts, Stephanie W ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Dept of Pharmacology and Toxicology ^*  (United States)

Author keywords

Vascular biology; Vein

Indexed keywords

ACETYLCHOLINE; ALLOPURINOL; ANGIOTENSIN II; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; ENDOTHELIN 1; HYDROGEN PEROXIDE; MESSENGER RNA; NORADRENALIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; XANTHINE OXIDASE; ANTIOXIDANT; ENZYME INHIBITOR; SUPEROXIDE DISMUTASE;

ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA; AORTA CONSTRICTION; ARTICLE; CAVA VEIN; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; METABOLISM; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VENOCONSTRICTION; ANIMAL; BIOSYNTHESIS; ENZYMOLOGY; GENETICS; IMMUNOHISTOCHEMISTRY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; THORACIC AORTA; WESTERN BLOTTING;

ALLOPURINOL; ANIMALS; ANTIOXIDANTS; AORTA, THORACIC; BLOTTING, WESTERN; CATALASE; ENZYME INHIBITORS; HYDROGEN PEROXIDE; IMMUNOHISTOCHEMISTRY; MALE; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUPEROXIDE DISMUTASE; VENAE CAVAE; XANTHINE OXIDASE;

EID: 54049158174     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00569.2008     Document Type: Article

References (44)

1. Ardanaz N, Pagano PJ. Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. Exp Biol Med (Maywood) 231: 237-251, 2006.
2. Banerjee D, Madhusoodanan UK, Sharanabasappa M, Ghosh S, Jacob J. Measurement of plasma hydroperoxide concentration by FOX-1 assay in conjunction with triphenylphosphine. Clin Chim Acta 337: 147-152, 2003.
3. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555: 589-606, 2004.
4. Borges F, Fernandes E, Roleira F. Progress towards the discovery of xanthine oxidase inhibitors. Curr Med Chem 9: 195-217, 2002.
5. Buetler TM, Krauskopf A, Ruegg UT. Role of superoxide as a signaling molecule. News Physiol Sci 19: 120-123, 2004.
6. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 35: 746-751, 2000.
7. Callera GE, Tostes RC, Yogi A, Montezano AC, Touyz RM. Endothelin-1-induced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms. Clin Sci (Lond) 110: 243-253, 2006.
8. Feig DI, Mazzali M, Kang DH, Nakagawa T, Price K, Kannelis J, Johnson RJ. Serum uric acid: a risk factor and a target for treatment? J Am Soc Nephrol 17: S69-73, 2006.
9. Fink GD, Johnson RJ, Galligan JJ. Mechanisms of increased venous smooth muscle tone in desoxycorticosterone acetate-salt hypertension. Hypertension 35: 464-469, 2000.
10. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148, 1994.
11. Guzik TJ, Olszanecki R, Sadowski J, Kapelak B, Rudzinski P, Jopek A, Kawczynska A, Ryszawa N, Loster J, Jawien J, Czesnikiewicz-Guzik M, Channon KM, Korbut R. Superoxide dismutase activity and expression in human venous and arterial bypass graft vessels. J Physiol Pharmacol 56: 313-323, 2005.
12. Guzik TJ, Sadowski J, Kapelak B, Jopek A, Rudzinski P, Pillai R, Korbut R, Channon KM. Systemic regulation of vascular NAD(P)H oxidase activity and Nox isoform expression in human arteries and veins. Arterioscler Thromb Vasc Biol 24: 1614-1620, 2004.
13. Houston M, Estevez A, Chumley P, Aslan M, Marklund S, Parks DA, Freeman BA. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem 274: 4985-4994, 1999.
14. Ikebuchi Y, Masumoto N, Tasaka K, Koike K, Kasahara K, Miyake A, Tanizawa O. Superoxide anion increases intracellular pH, intracellular free calcium, and arachidonate release in human amnion cells. J Biol Chem 266: 13233-13237, 1991.
15. Laakso JT, Teravainen TL, Martelin E, Vaskonen T, Lapatto R. Renal xanthine oxidoreductase activity during development of hypertension in spontaneously hypertensive rats. J Hypertens 22: 1333-1340, 2004.
16. Landmesser U, Spiekermann S, Preuss C, Sorrentino S, Fischer D, Manes C, Mueller M, Drexler H. Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol 27: 943-948, 2007.
17. Li L, Fink GD, Watts SW, Northcott CA, Galligan JJ, Pagano PJ, Chen AF. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation 107: 1053-1058, 2003.
18. Loomis ED, Sullivan JC, Osmond DA, Pollock DM, Pollock JS. Endothelin mediates superoxide production and vasoconstriction through activation of NADPH oxidase and uncoupled nitric-oxide synthase in the rat aorta. J Pharmacol Exp Ther 315: 1058-1064, 2005.
19. Martin DS, Rodrigo MC, Appelt CW. Venous tone in the developmental stages of spontaneous hypertension. Hypertension 31: 139-144, 1998.
20. McNally JS, Saxena A, Cai H, Dikalov S, Harrison DG. Regulation of xanthine oxidoreductase protein expression by hydrogen peroxide and calcium. Arterioscler Thromb Vasc Biol 25: 1623-1628, 2005.
21. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97: 916-931, 1998.
22. Munzel T, Afanas'ev IB, Kleschyov AL, Harrison DG. Detection of superoxide in vascular tissue. Arterioscler Thromb Vasc Biol 22: 1761-1768, 2002.
23. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 88: 10045-10048, 1991.
24. Ogden KK, Falck JR, Watts SW. The cytochrome p450 inhibitor ketoconazole potentiates 5-hydroxytryptamine-induced contraction in rat aorta. J Pharmacol Exp Ther 323: 606-613, 2007.
25. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58: 87-114, 2006.
26. Pang CC. Measurement of body venous tone. J Pharmacol Toxicol Methods 44: 341-360, 2000.
27. Papaharalambus CA, Griendling KK. Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc Med 17: 48-54, 2007.
28. Rothe CF. Reflex control of veins and vascular capacitance. Physiol Rev 63: 1281-1342, 1983.
29. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365-386, 2000.
30. Shi Y, Patel S, Davenpeck KL, Niculescu R, Rodriguez E, Magno MG, Ormont ML, Mannion JD, Zalewski A. Oxidative stress and lipid retention in vascular grafts: comparison between venous and arterial conduits. Circulation 103: 2408-2413, 2001.
31. Srivastava P, Hegde LG, Patnaik GK, Dikshit M. Role of endothelial-derived reactive oxygen species and nitric oxide in norepinephrine-induced rat aortic ring contractions. Pharmacol Res 38: 265-274, 1998.
32. Suzuki H, DeLano FA, Parks DA, Jamshidi N, Granger DN, Ishii H, Suematsu M, Zweifach BW, Schmid-Schonbein GW. Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. Proc Natl Acad Sci USA 95: 4754-4759, 1998.
33. Szasz T, Thakali K, Fink GD, Watts SW. A comparison of arteries and veins in oxidative stress: producers, destroyers, function, and disease. Exp Biol Med (Maywood) 232: 27-37, 2007.
34. Thakali K, Davenport L, Fink GD, Watts SW. Pleiotropic effects of hydrogen peroxide in arteries and veins from normotensive and hypertensive rats. Hypertension 47: 482-487, 2006.
35. Thakali K, Demel SL, Fink GD, Watts SW. Endothelin-1-induced contraction in veins is independent of hydrogen peroxide. Am J Physiol Heart Circ Physiol 289: H1115-H1122, 2005.
36. Thakali K, Fink GD, Watts SW. Arteries and veins desensitize differently to endothelin. J Cardiovasc Pharmacol 43: 387-393, 2004.
37. B receptor deficient rats. Vascul Pharmacol 49: 6-13, 2008.
38. Torrecillas G, Boyano-Adanez MC, Medina J, Parra T, Griera M, Lopez-Ongil S, Arilla E, Rodriguez-Puyol M, Rodriguez-Puyol D. The role of hydrogen peroxide in the contractile response to angiotensin II. Mol Pharmacol 59: 104-112, 2001.
39. Waring WS, McKnight JA, Webb DJ, Maxwell SR. Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes 55: 3127-3132, 2006.
40. Watts SW, Fink GD, Northcott CA, Galligan JJ. Endothelin-1-induced venous contraction is maintained in DOCA-salt hypertension; studies with receptor agonists. Br J Pharmacol 137: 69-79, 2002.
41. Watts SW, Rondelli C, Thakali K, Li X, Uhal B, Pervaiz MH, Watson RE, Fink GD. Morphological and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 292: H2438-H2448, 2007.
42. Watts SW, Thakali K, Smark C, Rondelli C, Fink GD. Big ET-1 processing into vasoactive peptides in arteries and veins. Vascul Pharmacol 47: 302-312, 2007.
43. Yamamoto J, Trippodo NC, MacPhee AA, Frohlich ED. Decreased total venous capacity in Goldblatt hypertensive rats. Am J Physiol Heart Circ Physiol 240: H487-H492, 1981.
44. Zhang DX, Gutterman DD. Mitochondrial reactive oxygen species-mediated signaling in endothelial cells. Am J Physiol Heart Circ Physiol 292: H2023-H2031, 2007.